Flibanserin | Addyi

ADDYI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to:

  • A co-existing medical or psychiatric condition
  • Problems within the relationship
  • The effects of a medication or other drug substance. (1)

Limitations of Use:

  • ADDYI is not indicated for the treatment of HSDD in postmenopausal women or in men. (1)
  • ADDYI is not indicated to enhance sexual performance. (1)

DOSAGE AND ADMINISTRATION

  • Recommended dosage is 100 mg taken once daily at bedtime (2.1)
  • ADDYI is dosed at bedtime because administration during waking hours increases risks of hypotension, syncope, accidental injury, and central nervous system (CNS) depression (2.1)
  • Discontinue treatment after 8 weeks if no improvement (2.3)
Asendin

Flibanserin | Addyi Prescribing Information Highlights

The following points are shortened, highlighted information from prescribing information for this drug. For the full prescribing information PDF, click the button below to be directed to the FDA PDF label for this drug.

FLIBANSERIN | ADDYI FULL PRESCRIBING INFO PDF